Research Grade Canakinumab (HF943016)

Datasheet Compartir producto Copiar información

Precio(USD): $

Especificación:

100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet

Vista general

Número de catálogo	HF943016
Descripción	Canakinumab (HF943016) is a research-grade recombinant antibody targeting Interleukin-1 beta. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Isotipo	IgG1-kappa
Sistema de expresión	Mammalian Cells
Clonalidad	Monoclonal
Objetivo	Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta
Nivel de endotoxinas	Please contact the lab for this information.
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P01584
Forma	Liquid
Buffer de almacenamiento	0.01M PBS, pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Nombres alternativos	ACZ885, 914613-48-2
Fondo	Interleukin-1 beta (IL1B/IL1F2) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6. IL1B is the therapeutic target of canakinumab (Ilaris). 1. Tominaga, K. et al. (2000) International immunology 12, 151-60. PMID: 10653850 2. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819 3. LaRock, CN. et al. (2016) Science immunology 1. PMID: 28331908 4. Van Damme, J. et al. (1985) Nature 314, 266-8. PMID: 3920526 5. Tian, XX. et al. (2021) International endodontic journal 54, 916-925. PMID: 33377178 6. Xia, S. et al. (2021) Nature 593, 607-611. PMID: 33883744
Nota	For research use only. Not suitable for clinical or therapeutic use.

Imágenes

Bioactivity

Detects Human IL1B/IL1F2 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Canakinumab
Flow cytometry

Flow-cytometry using PE anti-human IL1B antibody. 5637 cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an PE anti-human IL1B monoclonal antibody (Catalog HF943016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Flow cytometry

Flow-cytometry using anti-human IL1B antibody. 5637 cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human IL1B monoclonal antibody (Catalog HF943016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.